MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563884 | Name: JMS-17-2
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JMS-17-2 is a potent and selective antagonist of CX3CR1.

Chemical Structure

JMS-17-2
JMS-17-2
CAS#1380392-05-1

Theoretical Analysis

MedKoo Cat#: 563884

Name: JMS-17-2

CAS#: 1380392-05-1

Chemical Formula: C25H26ClN3O

Exact Mass: 419.1764

Molecular Weight: 419.95

Elemental Analysis: C, 71.50; H, 6.24; Cl, 8.44; N, 10.01; O, 3.81

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 2,650.00 Ready to ship
1g USD 3,850.00 2 Weeks
2g USD 6,450.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
JMS-17-2; JMS172; JMS 17 2; JMS17-2; JMS-172; JMS 17-2; JMS-17 2
IUPAC/Chemical Name
5-(3-(4-(4-Chlorophenyl)piperidin-1-yl)propyl)pyrrolo[1,2-a]quinoxalin-4(5H)-one
InChi Key
WOSMCMULWWHMIV-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H26ClN3O/c26-21-10-8-19(9-11-21)20-12-17-27(18-13-20)14-4-16-29-23-6-2-1-5-22(23)28-15-3-7-24(28)25(29)30/h1-3,5-11,15,20H,4,12-14,16-18H2
SMILES Code
O=C1C2=CC=CN2C3=C(C=CC=C3)N1CCCN4CCC(C5=CC=C(Cl)C=C5)CC4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM.
In vitro activity:
This study hypothesized that contact-independent proliferation might be more sensitive to CX3CR1 inhibition, so this study performed soft agar growth assays of PDAC cells with 21–26 d exposure to JMS-17-2. The small molecule antagonist potently inhibited colony formation of both AsPC-1 and MIAPaCa-2 cells with as little as 1 nM exposure (Fig. 4A and B). Reference: Biochem Biophys Res Commun. 2018 Jan 15;495(3):2264-2269. https://pubmed.ncbi.nlm.nih.gov/29274778/
In vivo activity:
These experiments showed that, in contrast to control animals presenting multiple tumors both in the skeleton and visceral sites, seven of the eight animals that received cancer cells pre-incubated with JMS-17-2 were found free of tumors (Fig. 4A and B). Notably, these animals were also found devoid of microscopic tumor foci and DTCs when inspected for fluorescent signals with multispectral microscopy-based imaging of frozen tissue sections (Fig. 4C). Reference: Mol Cancer Res. 2016 Jun;14(6):518-27. https://pubmed.ncbi.nlm.nih.gov/27001765/
Solvent mg/mL mM
Solubility
DMSO 32.5 77.39
Ethanol 10.0 23.81
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 419.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Stout MC, Narayan S, Pillet ES, Salvino JM, Campbell PM. Inhibition of CX3CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun. 2018 Jan 15;495(3):2264-2269. doi: 10.1016/j.bbrc.2017.12.116. Epub 2017 Dec 21. PMID: 29274778. 2. Shen F, Zhang Y, Jernigan DL, Feng X, Yan J, Garcia FU, Meucci O, Salvino JM, Fatatis A. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14(6):518-27. doi: 10.1158/1541-7786.MCR-16-0013. Epub 2016 Mar 21. PMID: 27001765; PMCID: PMC5070649.
In vitro protocol:
1. Stout MC, Narayan S, Pillet ES, Salvino JM, Campbell PM. Inhibition of CX3CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun. 2018 Jan 15;495(3):2264-2269. doi: 10.1016/j.bbrc.2017.12.116. Epub 2017 Dec 21. PMID: 29274778. 2. Shen F, Zhang Y, Jernigan DL, Feng X, Yan J, Garcia FU, Meucci O, Salvino JM, Fatatis A. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14(6):518-27. doi: 10.1158/1541-7786.MCR-16-0013. Epub 2016 Mar 21. PMID: 27001765; PMCID: PMC5070649.
In vivo protocol:
1. Shen F, Zhang Y, Jernigan DL, Feng X, Yan J, Garcia FU, Meucci O, Salvino JM, Fatatis A. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14(6):518-27. doi: 10.1158/1541-7786.MCR-16-0013. Epub 2016 Mar 21. PMID: 27001765; PMCID: PMC5070649.
1: Stout MC, Narayan S, Pillet ES, Salvino JM, Campbell PM. Inhibition of CX(3)CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun. 2018 Jan 15;495(3):2264-2269. doi: 10.1016/j.bbrc.2017.12.116. Epub 2017 Dec 21. PubMed PMID: 29274778. 2: Shen F, Zhang Y, Jernigan DL, Feng X, Yan J, Garcia FU, Meucci O, Salvino JM, Fatatis A. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14(6):518-27. doi: 10.1158/1541-7786.MCR-16-0013. Epub 2016 Mar 21. PubMed PMID: 27001765; PubMed Central PMCID: PMC5070649.